Stocktoria
RxSight, Inc. RXST
Nasdaq · XNAS · stock · Ophthalmic Goods · website · IPO 2021-07-30
RxSight, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 76.6% | 70.7% | 60.4% | 43.5% | 20.0% |
| Operating margin | -35.8% | -26.3% | -56.2% | -129.2% | -233.6% |
| Net margin | -29.0% | -19.6% | -54.6% | -136.2% | -215.5% |
| FCF margin | -14.4% | -16.0% | -52.1% | -125.0% | -206.5% |
| Return on assets | -12.5% | -8.6% | -26.6% | -44.5% | -25.3% |
| Return on equity | -14.1% | -9.8% | -30.3% | -74.3% | -35.2% |
| Debt / equity | — | — | 0.00× | 0.45× | 0.29× |
| Current ratio | 10.95 | 11.36 | 8.06 | 7.81 | 15.92 |
| Revenue growth | -3.9% | 57.1% | 81.8% | 116.9% | 53.9% |
Source: SEC EDGAR filings · CIK 0001111485 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.